Additionally, serum‐treated brain organoids recapitulate Alzheimer's disease‐like pathology, inducing levels of β‐secretase 1 and glycogen synthase kinase 3 α/β that lead to increased levels of Aβ and p‐Tau.46 The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.